Publikationen
Publikationen
Global M&A Trends in Health Industries
Health industries dealmakers gear up for a more favourable M&A environment in 2025
Portfolio gaps, supply chain uncertainty, changes in policy direction and other fundamental factors are expected to drive M&A by health industries companies in 2025. We believe a stronger US and European deal market, spurred by improving macroeconomic factors and the expectation of lighter US regulation, will lead to accelerated deal values and volumes over the next year.
In the pharmaceuticals and life sciences sector, large-cap pharma companies are looking to acquire innovative late-stage biotech companies to help further differentiate their portfolios and reposition for growth. For example, in July 2024 Biogen acquired Human Immunology Biosciences; in August 2024 Eli Lilly acquired Morphic and in January 2025 Johnson & Johnson announced their proposed acquisition of Intra-Cellular Therapies.
Was CFOs von Schweizer Spitälern bewegt
Die Rolle der CFOs in Schweizer Spitälern wird zunehmend komplexer – und entscheidender. In der dritten Ausgabe unseres Thesenpapiers zur Finanzfunktion von Schweizer Spitälern haben wir die drängendsten Themen und Herausforderungen analysiert. Basierend auf den Rückmeldungen von 101 CFOs haben wir fünf zentrale Thesen formuliert, ergänzt durch praxisnahe Handlungsempfehlungen.
KHZG und NIS-2: Synergieeffekte für ein digitales und sicheres Gesundheitswesen
Das Krankenhauszukunftsgesetz (KHZG) und die NIS2-Richtlinie sind zwei zentrale Regelwerke, die die Digitalisierung und IT-Sicherheit im deutschen Gesundheitswesen maßgeblich beeinflussen. Beide setzen Akzente in den Bereichen Digitalisierung und Cybersicherheit, wobei das KHZG finanzielle Förderung für Digitalisierungsprojekte bereitstellt und NIS-2 die Cybersicherheitsanforderungen in kritischen Infrastrukturen verschärft. Die Verbindung beider Regelungen zeigt sich in der Notwendigkeit, durch fortschreitende Digitalisierung auch die Cybersicherheit im Gesundheitswesen zu stärken.
The future of care
Healthcare faces multiple challenges that will only intensify in the years ahead. The global population is ageing and growing; by 2035, it could rise to nearly 9 billion people.
Opens in a new window. The incidences of chronic diseases such as diabetes, cancer and dementia are also growing, with global treatment costs for these conditions slated to reach US$47 trillion by 2030. Opens in a new window. Backlogs in state-funded health services are delaying routine treatments, and given the global shortage of healthcare workers, it is unlikely that this problem will resolve itself soon. Though newer medications, such as GLP-1 drugs, offer hope in treating a range of medical conditions, the cost is currently too high for the general population; a course of such obesity drugs in the US. Opens in a new window would set the average patient back US$500 a month. And inequalities in income and education further aggravate health inequalities. All the while, consumers and patients who have come to expect convenience and high levels of service in their retail experiences are now raising their expectations for their own healthcare.
© 2017 - 2025 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.
Follow us
